Quantitative Analysis to Discriminate Cutaneous Pharmacokinetic Profiles for Topical Drug Products

Poster Number
M1330-11-63

Sagar Shukla[1*], Tannaz Ramezanli[1], Elena Rantou[2], Katrin Tiffner[3], Thomas Birngruber[3], Frank Sinner[3,4], Sam G. Raney[1]

[1]Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD (U.S. FDA).
[2]Divison of Biometrics VIII, Office of Biostatistics, Office of Translational Sciences, CDER, U.S. FDA, Silver Spring, MD.
[3]HEALTH-Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft mbH, Neue Stiftingtalstrasse 2, 8010, Graz, Austria.
[4]Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
*Current affiliation: Division of Bioequivalence III, Office of Bioequivalence, OGD, CDER, U.S. FDA

Sagar.Shukla@FDA.HHS.gov

aaps PharmSci 360

PURPOSE

Dermal open flow microperfusion (dOFM) has been used to measure the cutaneous pharmacokinetics (PK) of topical dermatological drug products. Previous research in this area has shown that the dOFM technique has the potential to support a demonstration of bioequivalence (BE) for prospective generic topical dermatological drug products. The dOFM method should be designed to be sensitive at discriminating the differences in cutaneous bioavailability of the drug substance (e.g., from different formulations or different dose amounts). The purpose of this study was to investigate quantitative analyses using the pilot study, to establish the discrimination sensitivity of cutaneous PK studies using dOFM.

METHODS

The dOFM pilot study using EMLA® (lidocaine; prilocaine) topical cream, 2.5%;2.5% at different dose amounts (5, 10, or 15 mg/cm^2) and Oraqix® (lidocaine; prilocaine) periodontal gel at 10 mg/cm^2 in six healthy subjects conducted by Joanneum Research was used for this analysis.[1] The schematic of the study designs is shown in Figure 1.

Analyses of average bioequivalence [ABE], reference scaled ABE [SABE], and an assessment of difference (f_1) and similarity (f_2)[2] were evaluated for their ability to discriminate the cutaneous PK profiles from R (cream at 10 mg/cm^2) and T treatments (cream at 5 and 15 mg/cm^2 and gel at 10 mg/cm^2). The f_1 and f_2 factors were analyzed for two different parameters, using the percent concentration ($\%C_t = \frac{C_t}{C_{max\,T\,or\,R}}$), and percent area under the curve (AUC) profiles ($\%AUC_t = \frac{AUC_{0-t}}{AUC_{0-tlast\,T\,orR}}$). A bootstrap analysis was also performed. For the purpose of this study, cutaneous PK profiles were considered to be discriminated if **$f_1 > 15$ or $f_2 < 50$** and with bootstrap analysis when the 90% confidence interval (CI) for f_1 **>** 15 or for f_2 **<** 50.



Figure 1. Diagram illustrating the study design[1]

RESULTS

The cutaneous PK profiles from the R and T treatments were quantitatively discriminated by all analyses, except for the cream at 10 compared to 15 mg/cm^2, which was not discriminated by SABE nor f_1/f_2 analysis. For the purpose of this study, the bootstrap analysis consistently discriminated all the R and T comparisons of PK profiles based on f_1 and f_2 90% confidence intervals



Figure 2. Concentration versus time profiles (mean ± SE, n=6 volunteers) from the dOFM pilot study. (A: Lidocaine dermal concentrations, B: Prilocaine dermal concentrations).

Table 1. BE assessment comparing EMLA® cream at 10 mg/cm² with test treatments using ABE and SABE (SCI_{UB} [upper bound of the 95% CI]). Negative values indicate BE and lack of discrimination.

Dose vs Cream 10 mg/cm²	ABE Point Estimate (CI)		SCI_{UB} (m=1.25)	
	Lidocaine	Prilocaine	Lidocaine	Prilocaine
Cmax				
Cream 5 mg/cm² (n=12)	0.59 (0.45 – 0.79)	0.65 (0.52 – 0.82)	0.23	0.17
Cream 15 mg/cm² (n=12)	1.33 (0.96 – 1.83)	1.16 (0.85 – 1.57)	**-0.03**	**-0.05**
Gel 10 mg/cm² (n=6)	0.42 (0.34 – 0.51)	0.36 (0.30 – 0.44)	0.74	1.15
AUC				
Cream 5 mg/cm² (n=12)	0.64 (0.51 – 0.80)	0.59 (0.48 – 0.74)	0.16	0.30
Cream 15 mg/cm² (n=12)	0.99 (0.76 – 1.30)	0.96 (0.75 – 1.23)	**-0.18**	**-0.14**
Gel 10 mg/cm² (n=6)	0.49 (0.40 – 0.62)	0.35 (0.29 – 0.43)	0.56	1.29



Figure 3. Mean percent concentration versus time profiles (n=6 volunteers) from the dOFM pilot study (points). Shaded region represents the 5th and 95th percentiles from the bootstrap and the solid line represents the 50th percentile (n=1000).



Figure 4. Mean percent AUC versus time profiles (n=6 volunteers) from the lidocaine; prilocaine dOFM study (points). Shaded region represents the 5th and 95th percentiles from the bootstrap and the solid line represents the 50th percentile (n=1000).

Table 2. f_1 and f_2 analysis comparing lidocaine; prilocaine formulations to EMLA® cream 10 mg/cm² using data from the pilot study and from a bootstrap analysis (n=1000).

Dose vs Cream 10 mg/cm²	Point Estimate				Bootstrap (n=1000)			
	Percent conc profile		Percent AUC profile		Percent conc profile		Percent AUC profile	
	Lidocaine	Prilocaine	Lidocaine	Prilocaine	Lidocaine	Prilocaine	Lidocaine	Prilocaine
f_1								
Cream 5 mg/cm² (n=12)	65.5	63.4	64.6	63.1	63.1 (48.7 – 74.2)	61.3 (47.3 – 72.4)	62.1 (47.1 – 73.0)	61.0 (47.3 – 71.8)
Cream 15 mg/cm² (n=12)	30.5	24.1	14.6	13.3	39.4 (21.6 – 73.4)	33.2 (17.4 – 62.2)	30.3 (11.4 – 68.0)	25.7 (10.1 – 56.4)
Gel 10 mg/cm² (n=6)	70.2	76.0	69.4	75.7	67.2 (49.0 – 80.6)	74.2 (61.9 – 83.0)	65.7 (43.4 – 80.6)	73.5 (60.0 – 84.2)
f_2								
Cream 5 mg/cm² (n=12)	15.6	15.7	27.6	29.8	16.8 (14.8 – 19.9)	16.6 (13.9 – 22.7)	29.0 (23.6 – 37.5)	31.0 (25.8 – 38.4)
Cream 15 mg/cm² (n=12)	39.6	38.8	60.7	65.7	35.2 (27.9 – 42.3)	35.2 (27.2 – 43.9)	48.7 (33.1 – 65.1)	53.7 (38.2 – 70.2)
Gel 10 mg/cm² (n=6)	15.5	13.0	25.3	24.6	17.0 (14.0 – 22.3)	13.6 (11.0 – 18.6)	27.3 (20.9 – 38.2)	25.5 (21.6 – 31.1)

CONCLUSIONS

The presented analyses quantitatively discriminated profiles that were visually separated and tended not to discriminate between the PK of EMLA® cream at 10 mg/cm^2 compared to 15 mg/cm^2 dose, for which the profiles were largely overlapping (visually). Although the different quantitative approaches have the potential to provide an objective, dichotomous determination about whether two profiles are discriminated or not, the appropriateness of such analysis for the purpose of this study needs further evaluation. While an (S)ABE analysis of pilot study data would typically be under-powered, f_1/f_2-evaluation coupled with a bootstrap analysis may be a practical way to establish the sensitivity of a cutaneous PK methodology.

FUNDING / REFERENCE

Acknowledgements

Funding for this project was made possible, in part, by the U.S. Food and Drug Administration through grant 1U01FD005861. This project was supported in part by an appointment (Sagar Shukla) to the Research Participation Program at the FDA Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA. The views expressed in this poster are those of the authors and should not be construed to represent FDA's views or policies.

References

1. Tiffner K, Birngruber T, Schwargerle G, Bodenlenz M, Augustin T, Raml R, Kanfer I, Sinner F. Dermal pharmacokinetic endpoint studies to evaluate bioequivalence of topically applied lidocaine and prilocaine drug products. Poster session presented at: American Association of Pharmaceutical Scientists; 2019 Nov 3-6; San Antonio, TX.
2. Shah, V.P., Tsong, Y., Sathe, P. *et al.* In Vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2. *Pharm Res* **15,** 889–896 (1998). https://doi.org/10.1023/A:1011976615750

FDA U.S. FOOD & DRUG ADMINISTRATION

JOANNEUM RESEARCH HEALTH